HRP20150513T1 - Novi polimorf - Google Patents
Novi polimorf Download PDFInfo
- Publication number
- HRP20150513T1 HRP20150513T1 HRP20150513TT HRP20150513T HRP20150513T1 HR P20150513 T1 HRP20150513 T1 HR P20150513T1 HR P20150513T T HRP20150513T T HR P20150513TT HR P20150513 T HRP20150513 T HR P20150513T HR P20150513 T1 HRP20150513 T1 HR P20150513T1
- Authority
- HR
- Croatia
- Prior art keywords
- solid form
- form according
- nocturia
- vasopressin
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1005623.2A GB201005623D0 (en) | 2010-04-01 | 2010-04-01 | New polymorph |
| US34704810P | 2010-05-21 | 2010-05-21 | |
| EP11714079.8A EP2552910B1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
| PCT/GB2011/000500 WO2011121308A1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150513T1 true HRP20150513T1 (hr) | 2015-06-05 |
Family
ID=42228830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150513TT HRP20150513T1 (hr) | 2010-04-01 | 2011-03-31 | Novi polimorf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9079881B2 (enExample) |
| EP (1) | EP2552910B1 (enExample) |
| JP (1) | JP5802737B2 (enExample) |
| KR (1) | KR101792621B1 (enExample) |
| CN (1) | CN102918038B (enExample) |
| CA (1) | CA2795109C (enExample) |
| DK (1) | DK2552910T3 (enExample) |
| ES (1) | ES2538085T3 (enExample) |
| GB (1) | GB201005623D0 (enExample) |
| HR (1) | HRP20150513T1 (enExample) |
| HU (1) | HUE026442T2 (enExample) |
| ME (1) | ME02102B (enExample) |
| MX (1) | MX2012011382A (enExample) |
| PL (1) | PL2552910T3 (enExample) |
| PT (1) | PT2552910E (enExample) |
| RS (1) | RS53956B1 (enExample) |
| RU (1) | RU2559633C2 (enExample) |
| SI (1) | SI2552910T1 (enExample) |
| SM (1) | SMT201500107B (enExample) |
| WO (1) | WO2011121308A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201105537D0 (en) * | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN103755707B (zh) * | 2013-09-17 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅱ及其制备方法和用途 |
| CN104059070B (zh) * | 2013-09-17 | 2016-02-10 | 天津药物研究院有限公司 | 利希普坦晶型ⅰ及其制备方法和用途 |
| CN103694240B (zh) * | 2013-09-18 | 2015-11-18 | 天津药物研究院 | 利希普坦的溶剂合物及其制备方法和用途 |
| CN104140429B (zh) * | 2014-07-25 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅴ及其制备方法和用途 |
| US10413519B2 (en) * | 2015-07-22 | 2019-09-17 | Anavex Life Sciences Corp. | Crystal forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions |
| WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW359669B (en) | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
| PT1000059E (pt) | 1997-07-30 | 2004-12-31 | Wyeth Corp | Agonistas triciclicos de vasopressina |
| ATE277050T1 (de) | 1997-07-30 | 2004-10-15 | Wyeth Corp | Trizyclische vasopressin agoniste |
| CA2358892A1 (en) | 1999-02-04 | 2000-08-10 | Robert John Steffan | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| AU2849500A (en) | 1999-02-04 | 2000-08-25 | American Home Products Corporation | Tricyclic pyridine n-oxides vasopressin agonists |
| AU2603000A (en) | 1999-02-04 | 2000-08-25 | American Home Products Corporation | Thienylbenzoylbenzazepines as vasopressin agonists |
| EP1149097A2 (en) | 1999-02-04 | 2001-10-31 | American Home Products Corporation | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
-
2010
- 2010-04-01 GB GBGB1005623.2A patent/GB201005623D0/en not_active Ceased
-
2011
- 2011-03-31 US US13/637,873 patent/US9079881B2/en not_active Expired - Fee Related
- 2011-03-31 MX MX2012011382A patent/MX2012011382A/es active IP Right Grant
- 2011-03-31 ES ES11714079.8T patent/ES2538085T3/es active Active
- 2011-03-31 DK DK11714079T patent/DK2552910T3/en active
- 2011-03-31 CA CA2795109A patent/CA2795109C/en not_active Expired - Fee Related
- 2011-03-31 SI SI201130487T patent/SI2552910T1/sl unknown
- 2011-03-31 PT PT117140798T patent/PT2552910E/pt unknown
- 2011-03-31 RU RU2012146544/04A patent/RU2559633C2/ru not_active IP Right Cessation
- 2011-03-31 RS RS20150258A patent/RS53956B1/sr unknown
- 2011-03-31 HU HUE11714079A patent/HUE026442T2/en unknown
- 2011-03-31 JP JP2013501934A patent/JP5802737B2/ja not_active Expired - Fee Related
- 2011-03-31 EP EP11714079.8A patent/EP2552910B1/en active Active
- 2011-03-31 HR HRP20150513TT patent/HRP20150513T1/hr unknown
- 2011-03-31 KR KR1020127028111A patent/KR101792621B1/ko not_active Expired - Fee Related
- 2011-03-31 CN CN201180026714.4A patent/CN102918038B/zh not_active Expired - Fee Related
- 2011-03-31 ME MEP-2015-56A patent/ME02102B/me unknown
- 2011-03-31 PL PL11714079T patent/PL2552910T3/pl unknown
- 2011-03-31 WO PCT/GB2011/000500 patent/WO2011121308A1/en not_active Ceased
-
2015
- 2015-05-05 SM SM201500107T patent/SMT201500107B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201005623D0 (en) | 2010-05-19 |
| EP2552910A1 (en) | 2013-02-06 |
| CN102918038B (zh) | 2015-09-09 |
| HUE026442T2 (en) | 2016-06-28 |
| CA2795109C (en) | 2018-04-17 |
| PL2552910T3 (pl) | 2015-07-31 |
| CA2795109A1 (en) | 2011-10-06 |
| RS53956B1 (sr) | 2015-08-31 |
| JP2013523706A (ja) | 2013-06-17 |
| ME02102B (me) | 2015-10-20 |
| SI2552910T1 (sl) | 2015-06-30 |
| SMT201500107B (it) | 2015-07-09 |
| MX2012011382A (es) | 2013-01-29 |
| PT2552910E (pt) | 2015-05-13 |
| KR20130023218A (ko) | 2013-03-07 |
| JP5802737B2 (ja) | 2015-11-04 |
| DK2552910T3 (en) | 2015-04-07 |
| ES2538085T3 (es) | 2015-06-17 |
| RU2012146544A (ru) | 2014-05-10 |
| RU2559633C2 (ru) | 2015-08-10 |
| KR101792621B1 (ko) | 2017-11-02 |
| EP2552910B1 (en) | 2015-03-11 |
| CN102918038A (zh) | 2013-02-06 |
| US20140296213A1 (en) | 2014-10-02 |
| US9079881B2 (en) | 2015-07-14 |
| WO2011121308A1 (en) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150513T1 (hr) | Novi polimorf | |
| ES2659758T3 (es) | Antagonistas de receptores de 5-HT3 | |
| PL2054411T3 (pl) | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne | |
| IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
| HRP20192132T1 (hr) | Antagonist nk-1/nk-3 receptora za liječenje valunga | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| EP4574210A3 (en) | Kappa opioid receptor antagonists and products and methods related thereto | |
| NZ603789A (en) | Heteroaryl compounds and methods of use thereof | |
| JP2017514910A5 (enExample) | ||
| NZ603043A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| CL2009001125A1 (es) | Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. | |
| JP2012036197A5 (enExample) | ||
| PH12015500460A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| EA201390969A1 (ru) | Модуляторы глюкагонового рецептора | |
| CA2912921C (en) | Pyrazole compounds as modulators of fshr and uses thereof | |
| WO2012096929A3 (en) | Heteroaryl compounds and methods of use thereof | |
| MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| JP2013507408A5 (enExample) | ||
| WO2013188268A8 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| JP2014530818A5 (enExample) | ||
| MX356105B (es) | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. | |
| TN2013000533A1 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| EP1861358A4 (en) | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |